Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies
The first antimalarial developed specifically for babies is a step closer to reaching parts of the world where…
Novartis malaria treatment Coartem® Baby receives WHO prequalification
Novartis malaria treatment Coartem® Baby receives WHO prequalification April 26, 2026 | Sunday | News Coartem® (artemether-lumefantrine) Baby…
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment…
Vas Narasimhan on his rise to Novartis CEO
Guided by immigrant roots, public‑health purpose and a belief in “staying in the ring,” Novartis CEO Vas Narasimhan…
Turning personal experience into purpose-driven careers
For Arti, Giselle and Maria their desire for purpose began with a moment that changed everything and grew…
Global Fund boss warns aid cuts jeopardise progress against malaria
Climate change, conflicts and a lack of funding compounded by recent aid cuts are hurting hard-won gains in…
Breaking ground in Global Health
This past year has been active at Novartis in the malaria space. What has it meant for your…
Novartis receives approval for first malaria medicine for newborn babies and young infants
Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight…
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem®…